These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30827933)

  • 1. Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma.
    Zhong H; Chen J; Cheng S; Chen S; Shen R; Shi Q; Xu P; Huang H; Zhang M; Wang L; Wu D; Zhao W
    EBioMedicine; 2019 Mar; 41():167-174. PubMed ID: 30827933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma.
    Han Y; Yang J; Liu P; He X; Zhang C; Zhou S; Zhou L; Qin Y; Song Y; Sun Y; Shi Y
    Oncologist; 2019 Nov; 24(11):e1251-e1261. PubMed ID: 30952824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Externally Validated Nomogram for Predicting the Overall Survival of Patients With Diffuse Large B-Cell Lymphoma Based on Clinical Characteristics and Systemic Inflammatory Markers.
    Liu Y; Sheng L; Hua H; Zhou J; Zhao Y; Wang B
    Technol Cancer Res Treat; 2023; 22():15330338231180785. PubMed ID: 37551117
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic nomogram incorporating cytokines for overall survival in patients with newly diagnosed multiple myeloma.
    Cheng Q; Zhao F; Zhang B; Zhang Y; Cai L; Qiao B; Hu Y; Sun C
    Int Immunopharmacol; 2021 Oct; 99():108016. PubMed ID: 34385029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients.
    Ren L; Xu J; Li J; Xu T; Yang Y; Wang W; Ren Y; Gu S; Chen C; Wei Z; Zhuang J; Wang Z; Ji L; Cheng L; Wang W; Cheng Z; Ke Y; Yuan L; Liu P
    Clin Exp Med; 2023 Oct; 23(6):2583-2591. PubMed ID: 36639599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study.
    Cai J; Tian X; Ma S; Zhong L; Li W; Wang L; Guo L; Li Z; Wu Y; Zhong G; Huang H; Xia Z; Xia Y; Liu P; Su N; Fang Y; Zhang Y; Cai Q
    Br J Cancer; 2021 Aug; 125(3):402-412. PubMed ID: 34012033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of nomogram prognostic model for predicting OS in patients with diffuse large B-cell lymphoma: a cohort study in China.
    Li X; Xu Q; Gao C; Yang Z; Li J; Sun A; Wang Y; Lei H
    Ann Hematol; 2023 Dec; 102(12):3465-3475. PubMed ID: 37615680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
    Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Inflammatory-Nutritional Prognostic Scoring System for Patients with Diffuse Large B Cell Lymphoma.
    Wang Z; Bao Y; Xu Z; Sun Y; Yan X; Sheng L; Ouyang G
    J Inflamm Res; 2024; 17():1-13. PubMed ID: 38193043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and evaluation of a nomogram for predicting the survival outcomes of patients with diffuse large B-cell lymphoma based on International Prognostic Index scores and clinical indicators.
    Chen Y; Xu J; Meng J; Ding M; Guo Y; Fu D; Liu A
    Ann Transl Med; 2023 Jan; 11(2):71. PubMed ID: 36819580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
    Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
    Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
    Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
    J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
    Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW
    Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 16. Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome.
    Terol MJ; Tormo M; Martinez-Climent JA; Marugan I; Benet I; Ferrandez A; Teruel A; Ferrer R; GarcĂ­a-Conde J
    Ann Oncol; 2003 Mar; 14(3):467-74. PubMed ID: 12598355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study.
    Yang Y; Zhang YJ; Zhu Y; Cao JZ; Yuan ZY; Xu LM; Wu JX; Wang W; Wu T; Lu B; Zhu SY; Qian LT; Zhang FQ; Hou XR; Liu QF; Li YX
    Leukemia; 2015 Jul; 29(7):1571-7. PubMed ID: 25697894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
    Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
    Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
    Niitsu N; Iijima K; Chizuka A
    Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
    Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
    Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.